AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Orthocell expands into the US nerve repair market with four initial distributors
- Remplir rollout supported by inventory and efficient distribution model
- Targeting further expansion to reach 25 US states by mid-year
Regenerative medicine specialist Orthocell (ASX:OCC) has taken a major step into the US healthcare landscape, appointing its first four distributors for Remplir, the company's innovative nerve repair technology. The appointments follow the recent green light from the US Food and Drug Administration, clearing the path for immediate access to the US$1.6 billion nerve repair market.
These new distributors—specialists in nerve care—are based in Michigan, Virginia, Colorado, and Indiana. They will play a critical role in spearheading the adoption of Remplir within their regions, driving awareness and educating medical professionals while also initiating product sales. This launch is supported by a robust inventory Orthocell has established to meet anticipated demand.
Remplir is a collagen wrap designed to enhance surgical outcomes by supporting the repair and regeneration of damaged nerves. The product is currently available in markets such as the US, Australia, New Zealand, and Singapore, with approvals expected soon in Canada and Thailand. Regulatory submissions are also on track for Europe and the UK in the coming year, positioning the company to address a global market exceeding US$3.5 billion.
The US distributor model aligns with Orthocell's strategy of achieving efficient and cost-effective market entry. Each appointed distributor brings strong relationships with plastic and orthopaedic surgeons and established sales channels into key healthcare institutions. Operating under a commission-based structure, these partners are supported by a centralized logistics system that ensures seamless order fulfillment and customer service from a dedicated warehouse.
Orthocell aims to onboard six additional distributors by the end of June, potentially extending its reach to approximately 25 US states. This expansion is expected to significantly enhance revenue and move the company closer to breakeven.
Remplir is manufactured at Orthocell’s Western Australia facility using proprietary SMRT technology, which retains the natural structure of collagen to promote better integration with patient tissue. With the capability to produce up to 100,000 medical devices annually, the facility is already primed to support the US launch without additional capital investment.
With its lightweight nature, long shelf life, and ease of air transport, Remplir is well-suited for widespread distribution across the US. Orthocell’s strategic execution and operational readiness position it strongly for capturing a significant share in the global nerve repair sector.
